Racial disparities in immune-related adverse events of immune checkpoint inhibitors and association with survival based on clinical and biochemical responses

Figure 1 Kaplan-Meier curves. Progression free survival (A) and overall survival (B) of immune-related adverse events vs no immune-related adverse events using Kaplan-Meier methods with log-rank test for P value. irAE: Immune-related adverse events.

Figure 2 These differences were not seen on Kaplan-Meier analysis. Progression free survival (A) and overall survival (B) of endocrine immune-related adverse events vs no endocrine immune-related adverse events using Kaplan-Meier methods. irAE: Immune-related adverse events.

Figure 3 These did not translate to better survival probability on Kaplan-Meijer analysis. Progression free survival (A) and overall survival (B) based on race using Kaplan-Meier methods.